TABLE 3.
Multivariate analysis of factors associated with DFS in breast non‐pCR patients
| Characteristics | Multivariate (Model 1 a ) | Multivariate (Model 2 b ) | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p‐value | HR | 95% CI | p‐value | |
| cT | 0.006 | 0.006 | ||||
| 1 | 1 | 1 | ||||
| 2 | 0.98 | 0.44–2.18 | 0.962 | 0.97 | 0.44–2.17 | 0.945 |
| 3 | 1.68 | 0.71–3.97 | 0.238 | 1.66 | 0.70–3.96 | 0.250 |
| 4 | 2.53 | 1.01–6.34 | 0.047 | 2.51 | 0.99–6.33 | 0.051 |
| cN | 0.007 | 0.007 | ||||
| 0 | 1 | 1 | ||||
| 1 | 0.93 | 0.56–1.54 | 0.782 | 0.93 | 0.56–1.54 | 0.784 |
| 2 | 1.41 | 0.76–2.59 | 0.274 | 1.41 | 0.76–2.59 | 0.274 |
| 3 | 2.35 | 1.27–4.34 | 0.006 | 2.35 | 1.27–4.35 | 0.006 |
| Grade | 0.001 | 0.001 | ||||
| I–II | 1 | 1 | ||||
| III | 2.88 | 1.65–5.01 | <0.001 | 2.85 | 1.62–5.01 | <0.001 |
| NA | 1.95 | 1.11–3.43 | 0.021 | 1.93 | 1.09–3.43 | 0.021 |
| ER | ||||||
| Negative | 1 | 1 | ||||
| Positive | 0.91 | 0.43–1.95 | 0.815 | 0.91 | 0.43–1.94 | 0.805 |
| HER2 | ||||||
| Negative | 1 | 1 | ||||
| Positive | 1.36 | 0.71–2.60 | 0.356 | 1.44 | 0.74–2.82 | 0.280 |
| Molecular subtypes | <0.001 | <0.001 | ||||
| ER+HER2− | 1 | 1 | ||||
| HER2+ | 1.43 | 0.75–2.73 | 0.284 | 1.44 | 0.74–2.82 | 0.280 |
| TNBC | 2.67 | 1.68–4.27 | <0.001 | 2.69 | 1.68–4.30 | <0.001 |
| Pre‐NAC TILs | ||||||
| ≤10% | 1 | |||||
| >10% | 0.48 | 0.29–0.81 | 0.006 | |||
| Post‐NAC TILs | ||||||
| ≤10% | 1 | |||||
| >10% | 0.89 | 0.50–1.59 | 0.688 | |||
| TILs changes | 0.023 | |||||
| Group A | 1 | |||||
| Group B | 1.97 | 0.89–4.34 | 0.094 | |||
| Group C | 2.09 | 1.23–3.56 | 0.007 | |||
| Neoadjuvant‐targeted therapy | ||||||
| No | 1 | 1 | ||||
| Yes | 0.38 | 0.17–0.84 | 0.016 | 0.38 | 0.17–0.84 | 0.017 |
| NAC cycles | 0.185 | 0.182 | ||||
| ≤4 | 1 | 1 | ||||
| 5–7 | 1.04 | 0.65–1.66 | 0.871 | 1.03 | 0.65–1.65 | 0.890 |
| ≥8 | 0.64 | 0.36–1.15 | 0.135 | 0.64 | 0.35–1.14 | 0.130 |
Abbreviations: cN, clinical nodal stage; cT, clinical tumor stage; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor; NAC, neoadjuvant chemotherapy; TILs, tumor‐infiltrating lymphocytes; TNBC, triple negative breast cancer.
a
Model 1: the Cox proportional hazards model comprise pre‐NAC TILs, post‐NAC TILs, and other clinicopathological factors.
b
Model 2: the Cox proportional hazards model comprise changes of TILs and other clinicopathological factors. Group A: pre‐NAC TILs > 10% regardless of post‐NAC TILs; Group B: pre‐NAC TILs ≤ 10% and post‐NAC TILs > 10%; Group C: pre‐NAC and post‐NAC TILs ≤ 10%.